导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 6.21% | 1132/4773 |
| 近一周 | 0.02% | 838/5465 |
| 近一月 | -6.39% | 4161/5421 |
| 近一季 | -16.50% | 4503/5231 |
| 近半年 | 3.02% | 984/4920 |
| 近一年 | 9.25% | 1221/4394 |
| 近两年 | 111.47% | 513/2954 |
| 近三年 | 63.68% | 431/2253 |
| 成立以来 | 79.06% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.63% 2843/4961 |
39.49% 809/5312 |
- - |
- - |
| 2025 | 47.10% 576/4813 |
-2.36% 2877/3635 |
3.44% 1012/4076 |
47.29% 468/4524 |
-1.11% 2831/4813 |
| 2024 | 8.75% 1519/3463 |
-5.72% 1943/2808 |
-5.74% 1789/3014 |
25.36% 308/3129 |
-2.39% 2067/3463 |
| 2023 | -16.04% 1670/2656 |
1.89% 1489/2280 |
-5.67% 1515/2385 |
-9.46% 1828/2515 |
-3.51% 711/2655 |
| 2022 | -24.88% 1268/2207 |
-18.19% 1309/1919 |
8.20% 378/2016 |
-16.40% 1452/2113 |
1.52% 1237/2208 |
| 2021 | 18.82% 203/1822 |
-11.58% 1137/1255 |
25.31% 89/1330 |
4.85% 314/1466 |
2.28% 636/1822 |
| 2020 | 72.37% 63/1250 |
1.34% 146/1028 |
29.95% 67/1067 |
4.33% 958/1164 |
25.45% 26/1184 |
| 2019 | 17.23% 682/1092 |
26.54% 397/754 |
-14.72% 783/804 |
1.60% 383/850 |
6.92% 514/918 |
| 2018 | -43.20% 618/834 |
- - |
- - |
- - |
-16.14% 625/691 |
| 2017 | -0.90% 487/714 |
- - |
- - |
- - |
- - |
| 2016 | -19.54% 433/605 |
- - |
- - |
- - |
- - |
| 2015 | 42.73% 38/575 |
- - |
- - |
- - |
- - |
| 2014 | -0.42% 231/237 |
- - |
- - |
- - |
- - |
| 2013 | 20.55% 15/186 |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 诺安创业板指数增强(LOF)A VS. 长安沪深300非周期A(740101) |